Filing Details

Accession Number:
0001140361-15-012556
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-18 19:50:51
Reporting Period:
2015-03-16
Filing Date:
2015-03-18
Accepted Time:
2015-03-18 19:50:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197355 J Henry Fuchs C/O Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
Evp, Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-16 34,155 $21.51 124,105 No 4 M Direct
Common Stock Acquisiton 2015-03-16 5,845 $21.51 129,950 No 4 M Direct
Common Stock Disposition 2015-03-16 41,315 $123.57 88,635 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Common Stock Disposition 2015-03-16 34,155 $0.00 34,155 $21.51
Common Stock Stock Option (right to buy) Common Stock Disposition 2015-03-16 5,845 $0.00 5,845 $21.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-11-12 2020-05-11 No 4 M Direct
2,000 2010-11-12 2020-05-11 No 4 M Direct
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on March 2, 2015.
  2. The price in column 4 is a weighted average price. The price actually received ranged from $121.49 to $124.94. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
  3. Option grant vests 6/48ths on November 12, 2010, and 1/48th on the 10th day of every month thereafter.
  4. Reflect the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.